JPMorgan Chase & Co. Has $2.53 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JPMorgan Chase & Co. grew its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,780 shares of the company's stock after buying an additional 12,029 shares during the period. JPMorgan Chase & Co. owned 0.09% of IDEAYA Biosciences worth $2,527,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. FMR LLC increased its stake in IDEAYA Biosciences by 12.1% in the third quarter. FMR LLC now owns 12,635,653 shares of the company's stock valued at $400,297,000 after purchasing an additional 1,365,570 shares during the period. Janus Henderson Group PLC lifted its stake in shares of IDEAYA Biosciences by 26.7% in the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company's stock valued at $163,518,000 after purchasing an additional 1,086,356 shares during the period. State Street Corp boosted its holdings in IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock worth $105,112,000 after buying an additional 443,640 shares in the last quarter. Geode Capital Management LLC increased its position in shares of IDEAYA Biosciences by 9.8% in the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company's stock valued at $61,645,000 after buying an additional 172,838 shares in the last quarter. Finally, Logos Global Management LP grew its position in shares of IDEAYA Biosciences by 13.3% in the second quarter. Logos Global Management LP now owns 1,700,000 shares of the company's stock valued at $59,687,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 3.0 %

Shares of NASDAQ:IDYA traded up $0.67 on Tuesday, reaching $22.85. The company had a trading volume of 225,277 shares, compared to its average volume of 734,834. The stock has a market capitalization of $1.97 billion, a P/E ratio of -9.82 and a beta of 0.82. The stock has a 50-day moving average price of $25.95 and a 200 day moving average price of $32.15. IDEAYA Biosciences, Inc. has a twelve month low of $22.10 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period last year, the company earned ($0.46) earnings per share. On average, sell-side analysts predict that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IDYA shares. UBS Group started coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a "buy" rating and a $50.00 price objective for the company. Leerink Partnrs cut shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Stephens started coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They set an "overweight" rating and a $51.00 price target for the company. Finally, Wedbush reissued an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.67.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.